A multitude of new agents for the treatment of hematologic malignancies has been
introduced over the past decade. Hematologists, infectious disease specialists, stem cell …

The past 2 decades have seen a revolution in our approach to therapeutic
immunosuppression. We have moved from relying on broadly active traditional medications …

B-cell chronic lymphocytic leukaemia (CLL) is associated with immunosuppression and
patients are at increased clinical risk following SARS-CoV-2 infection. Covid-19 vaccines …

Patients with haematological malignancies are at high risk of infection because of various
mechanisms of humoral and cell-mediated immune deficiencies, which mainly depend on …

Bruton´ s tyrosine kinase (BTK) inhibitor (BTKi) s block the B-cell receptor (BCR) signaling
cascade by binding to the BTK enzyme preventing the proliferation and survival of malignant …

Immunocompromised patients with hematologic malignancies are more susceptible to
COVID-19 and at higher risk of severe complications and worse outcomes compared with …

Pneumococcal (PC) vaccination is recommended for patients with chronic lymphocytic
leukemia (CLL). However, response to vaccines has been investigated in a small series of …

Simple Summary The urgency of the COVID-19 pandemic has led to accelerated vaccine
development within less than a year. Emerging data suggest that the ability of patients with …

The novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) has been first
described in December 2019 in Wuhan, China, and has led to a worldwide pandemic ever …

Chronic lymphocytic leukaemia (CLL) is the most common leukaemia with infections a
leading cause of morbidity and mortality. Recently there has been a paradigm shift from the …